
Janux Therapeutics (JANX) Stock Forecast & Price Target
Janux Therapeutics (JANX) Analyst Ratings
Bulls say
Janux Therapeutics is a biopharmaceutical company with a strong focus on developing tumor-activated immunotherapies for cancer. Its proprietary TRACTr, TRACIr, and ARM platforms utilize tumor-activated masking technology, which improves specificity and safety. With a robust pipeline of potential treatments, impressive financial backing, and ongoing clinical trials showing promising results, the company is well-positioned for success and has the potential to transform T-cell engager approaches in both oncology and autoimmune diseases.
Bears say
Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing tumor-activated immunotherapies for cancer. While its proprietary technology allows for the development of distinct bispecific platforms, the company's lead asset, JANX007, may face challenges in the competitive TCE landscape due to potential tolerability issues. With a projected peak revenue opportunity of only $1.8 billion by 2035, the company's other assets, including JANX013 and JANX014, may offer potential value drivers. However, failure to meet efficacy or safety expectations and competition from current and future therapies pose risks to the company's potential for success.
This aggregate rating is based on analysts' research of Janux Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Janux Therapeutics (JANX) Analyst Forecast & Price Prediction
Start investing in Janux Therapeutics (JANX)
Order type
Buy in
Order amount
Est. shares
0 shares